Zhitong Finance App News, Weilizhibo-B (09887.HK) issued an announcement. At the 2026 Annual Meeting of the European Society of Medical Oncology (2026 ESMO), the key registered phase IIB clinical study for the single-agent treatment of advanced extrapulmonary neuroendocrine cancer (“EP-NEC)” has been selected for the latest breakthrough abstract (LBA) and qualified for oral report presentation. The label marks breakthrough research related to breakthrough research Innovative nature and major clinical trials Value. The research results are expected to change existing clinical practice and reshape the standard treatment pattern for advanced EP NEC. It is worth noting that in 2026, ESMO's three studies were selected for oral presentation, and the number selected was among the highest among Chinese pharmaceutical companies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.